Effect of Antiallergic Agents and Bronchial Hypersensitivity in Short-term Bronchial Asthma (6)
As shown in Table 4, improvement in bronchial hypersensitivity was observed in all six (100 percent) of group A, and only two out of ten (20 percent) in group B. There was a significant difference in the improvement rate between group A and B. Therefore, a higher rate of bronchial hypersensitivity-improved cases observed in group A did not seem to be simply due to the improvement of the baseline FEVp. Cheap Diskus Advair
Changes in Severity of Asthmatic Symptoms by Antiallergic Agents
We examined the changes in severity of asthmatic symptoms by treatment with antiallergic agents. As shown in Figure 2, the percentage of symptom-free cases increased from 18 to 82 percent in group A, 8 to 31 percent in group B, 0 to 25 percent in group C, 0 to 11 percent in group D. Remarkable improvement of asthmatic symptoms was observed in the shortterm cases treated with antiallergic agents.
Changes in Bronchial Hypersensitivity in a Patient Treated with DSCG
Bronchial hypersensitivity in the present patient was markedly improved by treatment with DSCG (Fig 3). The patient was a 27-year-old man with a history of asthmatic attacks for two weeks. The laboratory data indicated that his asthmatic type was extrinsic: IgE, 790 U/ml; IgERAST was positive for mite and orchard grass pollen.
Table 4—Improvement of Bronchial Hypersensitivity in Patients Whose FEV, Change was Less Than 10%
|Group||Patients with FEV, Change < 10%||BH-ImprovedCases|
|A (n = 11)||6/11 (54.5)||6/6 (100%)|
|B (n = 13)||10/13 (76.9)||2/10 (20%)|
|C (n = 4)||1/4 (25.0)||0/1 (0%)|
|D (n = 9)||6/9 (66.7)||0/6 (0%)|
Figure 2. Changes in severity of asthmatic symptoms in four groups. I, severity of asthmatic symptoms at initial visit; B, severity of asthmatic symptoms before administration of antiallergic agents; and A, severity of asthmatic symptoms after administration of antiallergic agents. Striped areas, severe; heavy hatch, moderate; light hatch, mild; and open areas, symptom-free.
Figure 3. A short-term case whose bronchial hypersensitivity was markedly improved by the treatment with DSCG. A (upper). Changes in bronchial hypersensitivity. B (lower). Changes in dose-re-sponse curve of histamine inhalation test, a, Just before DSCG administration; b, two months after DSCG administration; c, Five months after DSCG administration; and d, Twenty-two months after DSCG administration.